Quest for the right Drug

|
עמוד הבית / פרסולאט 10 / מידע מעלון לרופא

פרסולאט 10 PRESSOLAT ® 10 (NIFEDIPINE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות בשחרור מושהה : TABLETS MODIFIED RELEASE

Pregnancy & Lactation : הריון/הנקה

4.6     Fertility, Pregnancy and Lactation

Pregnancy
Pressolat should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine (see section 4.4).

In animal studies, nifedipine has been shown to produce embryotoxicity, foetotoxicity and teratogenicity (see section 5.3).

There are no adequate and well-controlled studies in pregnant women.

From the clinical evidence available a specific prenatal risk has not been identified, although an increase in perinatal asphyxia, caesarean delivery, as well as prematurity and intrauterine growth retardation have been reported. It is unclear whether these reports are due to the underlying hypertension, its treatment, or to a specific drug effect.

The available information is inadequate to rule out adverse drug effects on the unborn and newborn child.
Therefore any use in pregnancy requires a very careful individual risk benefit assessment and should only be considered if all other treatment options are either not indicated or have failed to be efficacious.

Acute pulmonary oedema has been observed when calcium channel blockers, among others nifedipine, have been used as a tocolytic agent during pregnancy (see section 4.8), especially in cases of multiple pregnancy (twins or more), with the intravenous route and/or concomitant use of beta-2 agonists.

Breastfeeding
Nifedipine is excreted in the breast milk. The nifedipine concentration in the milk is almost comparable with mother serum concentration. For immediate release formulations, it is proposed to delay breastfeeding or milk expression for 3 to 4 hours after drug administration to decrease the nifedipine exposure to the infant (see section 4.4).

Fertility
In single cases of in vitro fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa’s head section that may result in impaired sperm function. In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation, and where no other explanation can be found, calcium antagonists like nifedipine should be considered as possible causes.


שימוש לפי פנקס קופ''ח כללית 1994 Hypertension, vasospastic angina (Prinzmetal), chronic stable angina
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

BAYER ISRAEL LTD

רישום

040 75 25890 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

15.02.17 - עלון לרופא

עלון מידע לצרכן

13.02.17 - עלון לצרכן 08.01.17 - עלון לצרכן עברית 26.03.14 - החמרה לעלון 14.12.16 - החמרה לעלון

לתרופה במאגר משרד הבריאות

פרסולאט 10

קישורים נוספים

RxList WebMD Drugs.com